FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

vvasimigtori,	D.O. 20040	

OMB APPROVAL										
OMB Number:	3235-02									

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

l	OWD ALL INC	7 V/\L				
	OMB Number:	3235-0287				
l	Estimated average burd	en				
l	hours per response:	0.5				

Name and Address of Reporting Person* Name Po				2. Issuer Name and Ticker or Trading Symbol Y-mAbs Therapeutics, Inc. [YMAB] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)								er					
Kruse Bo				-								X Directo	r		10% Ow	ner	
(Last)	(F	irst)	(Middle)	3	Date of Earliest Transaction (Month/Day/Year)					_	X Officer below)	(give title		Other (s below)	pecify		
C/O Y-MABS THERAPEUTICS, INC.					01/07/2020						EVP, CFO, Secy & Treas.						
230 PARK AVENUE, SUITE 3350																	
(Street)				4	4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Individual or Joint/Group Filing (Check Applicable Line)						
NEW YORK NY 10169													, ,				
													Form filed by More than One Reporting Person			ing	
(City)	(S	tate)	(Zip)														
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
Date			. Transacti ate Month/Day	Execution Date,		3. Transac Code (Ir				Beneficia Owned F	Forn lly (D) o ollowing (I) (Ir	Form: (D) or	m: Direct I or Indirect I Instr. 4)	7. Nature of Indirect Beneficial Ownership			
							Code	v	Amount	mount (A) or (D)		Transact	Reported Transaction(s) (Instr. 3 and 4)			Instr. 4)	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date if any (Month/Day/Yea	Code	Transaction Code (Instr. 8) Deriva Securi Acquir or Disp of (D) (Derivative Ex		Expiration Date (Month/Day/Year)		7. Title and Amou of Securities Underlying Derivative Securi (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	derivativ Securitie	e Own s Forn dly Direc or In g (I) (Ir	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D)							Date Exercisable		xpiration ate	Title	Amount or Number of Shares		(Instr. 4)				
Employee Stock Option (right to buy)	\$30.34	01/07/2020		A		130,000		(1)	0:	1/07/2030	Common Stock	130,000	\$0	130,00	00	D	

Explanation of Responses:

1. The stock option shall vest and become exercisable as to 25% of the shares subject to the option on January 7, 2021, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.

/s/ Bo Kruse

01/09/2020

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.